There is substantial experience attempting to treat KRAS-mutated lung adenocarcinoma with the use of RAS/RAF multikinase inhibitors as well as inhibitors of both upstream and downstream proteins important in RAS signaling. We review the disappointing results from these clinical trials in lung cancer. ...
Panelists discuss first-line treatment decision-making for KRAS-mutated metastatic non–-small cell lung cancer (NSCLC), focusing on the selection of targeted therapies and factors influencing clinical choices.This is a modal window. The Playback API request failed for an unknown reason Error Cod...
There’s a lot of talk about combining direct KRAS G12C inhibitors with SHIP inhibitors, SOS inhibitors, other proteins in that same MAP kinase pathway, ERK inhibitors even. The question will be whether 2 hits increases the toxicity 2-fold, which is what we found when ...
Conclusions Our real-life data regarding KRAS-mutated PDAC patients who received treatment with the MEK inhibitor trametinib combined with hydroxychloroquine after experiencing disease progression are consistent with the preclinical data, pointing to the clinical benefits of this regimen....
MGO scavengers inhibit AKT and resensitize KRAS-mutated CRC cells to cetuximab in vivo. This study establishes a link between MGO and AKT activation and pinpoints this oncometabolite as a potential target to tackle EGFR-targeted therapy resistance in CRC....
Amgen’s first KRAS targeted therapy, Lumakras (ingredient: sotorasib), demonstrated consistent clinical benefits in the longest follow-up of patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC).On Sunday, Amgen released the two-year data o
Scientists have identified biomarkers that may help predict whether patients with KRAS-mutated non-small cell lung cancer (NSCLC) will respond to concurrent treatment with an MEK inhibitor and a PI3 kinase inhibitor, a drug combination currently being investigated in ongoing clinical trials. The discov...
The FDA has approved sotorasib as the first treatment for adult patients with non–small cell lung cancer whose tumors harbor KRAS G12C mutations and who have received at least 1 prior systemic therapy. FDA The FDA has approved sotorasib (Lumakras) as the first treatment for adult patients...
Zoldonrasib showed preliminary antitumor activity and manageable adverse events in KRAS G12D–mutated PDAC, per phase 1 trial data. Pancreatic cancer anatomy concept: © ЛилияЗахарчук - stock.adobe.com In an ongoing phase 1 trial (NCT06040541), zoldonra...
Korea. "A response of this magnitude could not be expected with other chemotherapy or immunotherapy in pre-treated KRAS-mutated patients, suggesting that KRASG12C is a therapeutic target." She considered the finding is potentially practice-changing although further studies are needed as long-term ...